Job 22 - Assort Design

Request JD-000022 Medical Affairs

Audience: Medical Affairs • completed

Routing confidence: 85% • Candidates: Medical Affairs, R&D, Commercial

Routing reasons: The document focuses on a specific medical condition (MASH) and its treatment, indicating content aimed at healthcare professionals.; References to FDA-approved treatments, disease pathology, and scientific citations suggest it is intended for a medically informed audience.; The presence of patient advocacy information and therapeutic focus aligns with the medical affairs domain.

Needs review: fewer than 3 supported citations found.

Source url

Show full document

Home - Madrigal Medical Professionals Contact Us Search for: Back Region United States Germany About Our Leaders Community Corporate Giving Therapeutic Focus What is MASH? Our Medicine Careers & Culture Investors & Media Leading the Fight Against MASH Our innovative research led to the first breakthrough in MASH treatment. And we’re just getting started. More About Madrigal COMPANY NEWS European Commission Grants Approval of Our Medicine. Read more Pam, patient advocate Delivering a Breakthrough Treatment Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse liver scarring (fibrosis) and resolve MASH before patients experience the devastating complications of cirrhosis. Madrigal’s ambitious research program led to the first U.S. Food and Drug Administration (FDA)-approved treatment in MASH. Our Medicine Shining a Light on MASH Shining a Light on MASH Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious form of fatty liver disease that occurs when fat in the liver becomes toxic, damaging liver cells. The chronic and progressive nature of the disease can cause significant damage over time, including inflammation and scarring, or fibrosis. Fibrosis can progress quickly and be unpredictable, often resulting in cirrhosis and decompensated liver disease. MASH is the leading cause of liver transplantation in the U.S. for women and is expected to soon become the leading cause for men. More About MASH Careers & Culture Interested in transforming care of people living with MASH? Learn more about Madrigal’s purpose, Core Values and culture. Explore Life at Madrigal News Read More News Read More News Events View More Events View More Events References Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8(10):661-8. Heyens LJM, Busschots D, Koek GH, et al. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med (Lausanne) . 2021;8:615978. Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol . 2018;113(11):1649-1659. Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open . 2020;3(2):e1920294. About Therapeutic Focus Our Medicine Careers & Culture Investors & Media Contact Us Terms of Use Transparency Privacy Cookies U.S. Consumer Health Privacy Manage Cookie Preferences Your Privacy Choices © 2026 Madrigal Pharmaceuticals, Inc. All rights reserved. The information on this website is intended for residents of the United States only. Madrigal Patient Support is a registered trademark of Madrigal Pharmaceuticals, Inc. US-CORP-MDGL-00002 You are now leaving madrigalpharma.com. By clicking this link you will be redirected to a website that is neither owned nor controlled by Madrigal. Madrigal is not responsible for the content or services of this site. Continue Stay Here

Madrigal Pharmaceuticals pioneered the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), addressing a critical unmet need in halting liver fibrosis and preventing serious liver-related complications.

5 bullets 7 tags 7 clues No high-risk flags

📊

View Analysis

Full breakdown — bullets, mind map, citations, risk & scorecard

📄

View Source

Original document text

One-line Summary

Decision Bullets

Scientific Summary: MASH involves toxic fat-induced liver cell damage progressing to fibrosis and cirrhosis, necessitating novel therapeutics to prevent end-stage liver disease. No citation found
Evidence Gaps: Long-term efficacy and safety data of the new treatment in diverse populations remain limited. No citation found
Medical Insights: Early intervention targeting fibrosis could reduce liver transplant rates and mortality associated with MASH. No citation found
Stakeholder Considerations: Patient advocacy is critical given disease burden, and payers must evaluate cost-effectiveness of novel therapies. No citation found
Next Steps: Further research needed on biomarkers for non-invasive diagnosis and therapy monitoring, plus expanded clinical trials. No citation found

Mind Map

mindmap
  root((Madrigal & MASH))
    Research
      - First FDA-approved treatment
      - Novel therapeutics development
    Disease
      - Metabolic dysfunction-associated steatohepatitis (MASH)
      - Progresses to fibrosis, cirrhosis, liver failure
      - Leading cause of liver transplant
    Clinical Impact
      - Halting/reversing liver scarring
      - Preventing advanced liver disease
    Evidence Gaps
      - Long-term safety/efficacy
      - Biomarker validation
    Stakeholders
      - Patients & advocates
      - Healthcare providers
      - Payers
    Next Steps
      - Expanded clinical trials
      - Non-invasive diagnostics
      - Monitoring treatment outcomes

#	Bullet	Supporting Quote	Level
1	Scientific Summary: MASH involves toxic fat-induced liver cell damage progressing to fibrosis and cirrhosis, necessitating novel therapeutics to prevent end-stage liver disease.	—	None
2	Evidence Gaps: Long-term efficacy and safety data of the new treatment in diverse populations remain limited.	—	None
3	Medical Insights: Early intervention targeting fibrosis could reduce liver transplant rates and mortality associated with MASH.	—	None
4	Stakeholder Considerations: Patient advocacy is critical given disease burden, and payers must evaluate cost-effectiveness of novel therapies.	—	None
5	Next Steps: Further research needed on biomarkers for non-invasive diagnosis and therapy monitoring, plus expanded clinical trials.	—	None

Attempt Timeline

Attempt 1

Attempts

Attempt 1 — Passed
Madrigal Pharmaceuticals pioneered the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), addressing a critical unmet need in halting liver fibrosis and preventi

View Debug

Trace Legend

Route Audience: Classifies the document into an audience.
Specialist Generate: Produces one-line summary, key clues, decision bullets, mind map, and tags.
Evaluate: Checks required sections, word count, and 3–5 bullet constraint.
Persist Attempt: Saves the attempt record.
Next Step: Decides whether to revise or persist results.
Persist Results: Saves final clues and tags at the document level.